Stirling Products (ASX: STI) advises that its North American wholly-owned subsidiary, Stirling Products North America Inc. (SPNA), has offered terms and conditions to Distribution Claude Levesque Inc. (DCL) to sell and distribute Stirling's beta glucan product ProVale. Under the terms of the Memorandum of Understanding, both parties will have three months to finalize a formal agreement.
Stirling Products Limited (ASX: STI) advises shareholders that it has signed a Term Sheet and Letter of Understanding with the company Equine Healthcare Limited, based in the United Kingdom, for the first option to license, manufacture and distribute its patented 'early detection device' for respiratory disorders.
Stirling Products North America Inc (trading as Progressive BioActives Inc) and PEI Pork Plus Inc have signed an MOU which provides Stirling with the opportunity to become the exclusive sales and distribution partner for PEI Pork's Omega-3 Meat Enhancement Technology. The MOU covers all livestock applications including swine, poultry, lamb and cattle markets in Australia, New Zealand and various Asian Pacific regions.
Stirling Products Limited (ASX: STI) advises shareholders that its North American subsidiary (Stirling Products North America Inc. trading as Progressive BioActives Inc.), has signed a Term sheet with US-based aquaculture company Aqua Bounty Technologies (London stock exchange symbol ABTX) to begin trials of ProVale(tm) in the Chilean salmon market.
Stirling Products (ASX: STI) advises that it has received written notification of registration approval under the new Feeds Act classification for Yeast Cell Wall Beta Glucan products by the Canadian Food Inspection Agency (CFIA). The two products, ProVale Yeast Cell Wall for Livestock Feeds and ProVale Yeast Cell Wall Premix for Livestock Feeds are now recognized as containing an independently validated and minimum quantity of activated beta glucan from purified yeast cell wall material under the recently amended guidelines implemented by the CFIA.
Stirling Products (ASX: STI) advises that it has recently received information from its current Distribution partner in South Africa (Afgri Operations Pty Limited) that the MCC has approved the application for R-salbutamol to be included under Section 36 of the Stock Remedy Act. The approval means that Afgri, on behalf of Stirling Products, can now conduct the necessary trials for registration and commercialisation under this Act rather than the more stringent MCC process."
The Directors of Stirling Products Limited (ASX: STI) are pleased to announce that the Company has completed a private placement of 42,770,000 fully paid ordinary shares at $0.05 raising A$2,138,500 million. The placement of these shares was approved by Shareholders at the Company's Annual General Meeting held on 22 November, 2007.
